Novel experimental therapies for atherosclerosis : a genomics based
approach
Wanrooij, E.J.A. van
Citation
Wanrooij, E. J. A. van. (2007, September 26). Novel experimental therapies for
atherosclerosis : a genomics based approach. Retrieved from
https://hdl.handle.net/1887/12357
Version: Corrected Publisher’s Version
License: Licence agreement concerning inclusion of doctoral thesis in the
Institutional Repository of the University of Leiden
Downloaded from: https://hdl.handle.net/1887/12357
Curriculum Vitae
Eva van Wanrooij was born on the 29th of March 1979 in Weert, The Netherlands. After her secondary education at the Philips van Horne SG, she obtained a masters degree in Bio-Pharmaceutical sciences at Leiden University in 2002. For her master thesis entitled “Differential gene expression during atherogenesis” she received the Susanne Hovinga award for best bio-medical master thesis. In the same year she started the PhD project described in this thesis under supervision of Dr. Johan Kuiper and Prof. Theo van Berkel.
Vascular genomics, focusing on activation and infiltration of leukocytes in the vessel wall was the main area of research. Various aspects of these studies have been published and presented at international conferences. Next to her scientific research, she obtained a Bachelor of Law degree at Leiden University Law School in 2006, and will finish a Master of Corporate Law at Leiden University in September 2007. In October 2007 she will start as Patent Attorney Trainee at Philips Intellectual Properties & Standards in Eindhoven.
List of publications Accepted manuscripts
Van Wanrooij EJA, van Puijvelde GHM, de Vos P, Yagita H, van Berkel TJC, Kuiper J. : Interruption of the Tnfrsf4/Tnfsf4 (OX40/OX40L) pathway attenuates atherogenesis in low-density lipoprotein receptor-deficient mice. Arterioscler Thromb Vasc Biol Jan;27(1):204-10
van Wanrooij EJA, Happe H, Hauer A, de Vos P, Imanishi T, Fujiwara H, van Berkel TJ, Kuiper J. HIV Entry Inhibitor TAK-779 Attenuates Atherogenesis in Low-Density Lipoprotein Receptor-Deficient Mice. Arterioscler Thromb Vasc Biol. Dec;25(12):2642-7
Van Wanrooij EJA, De Jager SCA, Van Es T, de Vos P, Birch HL, Owen DA, Watson RJ, Biessen EAL, Chapman GA, Van Berkel TJC, Kuiper J: The CXCR3 antagonist NBI-74330 attenuates atherosclerotic plaque formation in LDL receptor deficient mice. Conditionally accepted for publication in Arterioscler Thromb Vasc Biol.
Hauer AD, van Puijvelde GHM, Peterse N, de Vos P, van Weel V, vvan Wanrooij EJA, Biessen EAL, Quax PHA, van Berkel TJC, Niethammer AG, Reisfeld RA, Kuiper J: Induction of cellular immunity against VEGFR2 by DNA vaccination attenuates atherosclerosis. Accepted for publication in Arterioscler Thromb Vasc Biol.
J. Kuiper, GHM van Puijvelde, EEJA van Wanrooij, AD Hauer, TJC van Berkel.
Immunomodulation of the inflammatory response in atherosclerosis. Curr. Opin.
Lipidol. 2007 in press.
Meurs I, Hoekstra M, vvan Wanrooij EJ, Hildebrand RB, Kuiper J, Kuipers F, Hardeman MR, Van Berkel TJ, Van Eck M. HDL cholesterol levels are an important factor for determining the lifespan of erythrocytes. Exp Hematol.
2005 Nov;33(11):1309-19.
Guo J, de Waard V, Van Eck M, Hildebrand RB, vvan Wanrooij EJ, Kuiper J, Maeda N, Benson GM, Groot PH, Van Berkel TJ. Repopulation of Apolipoprotein E Knockout Mice With CCR2-Deficient Bone Marrow Progenitor Cells Does Not Inhibit Ongoing Atherosclerotic Lesion Development.
Arterioscler Thromb Vasc Biol. 2005 May;25(5):1014-9
Reinier A. Boon, Joost O. Fledderus, Oscar L. Volger, EEva van Wanrooij, Evangelia Pardali, Frank Weesie, Johan Kuiper, Hans Pannekoek, Peter ten Dijke and Anton J.G. Horrevoets. KLF2 suppresses TGF- beta signaling in
endothelium through induction of Smad7 and inhibition of AP-1. Arterioscler Thromb Vasc Biol. 2007 Mar;27(3):532-9
Hoekstra M, Stitzinger M, vvan Wanrooij EJ, Michon IN, Kruijt JK, Kamphorst J, Van Eck M, Vreugdenhil E, Van Berkel TJ, Kuiper J. Microarray analysis indicates an important role for FABP5 and putative novel FABPs on a Western- type diet. J Lipid Res. 2006 Oct;47(10):2198-207
Submitted manuscripts
EJA van Wanrooij, P. de Vos, G. Bixel, D. Vesteweber, T.J.C van Berkel, J.
Kuiper. Vaccination against CD99 inhibits atherogenesis in LDL receptor deficient mice. Submitted for publication.
Hauer AD, Habets KL, vvan Wanrooij EJA, de Vos P, van Berkel TJC, Reisfeld RA, Kuiper J. Introduction of cellular immunity against TIE2 by DNA vaccination attenuates atherosclerosis. Submitted for publication..
Habets KLL, van Puijvelde GHM, van Duivenvoorde LM, Litjens REJN, vvan Wanrooij EJA, de Vos P, van der Marel GA, Overkleeft HS, Cohen Tervaert JW, van Berkel TJC, Toes R, Kuiper J.: Immunomodulation with OCH-pulsed dendritic cells attenuates atherosclerosis. Submitted for publication
van Puijvelde GHM, van Es T, van Wanrooij EJA, de Vos P, van der Zee R, van Eden W, van Berkel TJC, Kuiper J.: Induction of oral tolerance to HSP60 or an HSP60-peptide activates T cell regulation and reduces atherosclerosis. Submitted for publication.
van Puijvelde GHM, Habets KLL, van Duivenvoorde LM, vvan Wanrooij EJA, de Vos P, Cohen Tervaert JW, van Berkel TJC, Toes R, Kuiper J. : Immunotherapy of atherosclerosis using dendritic cells. Submitted for publication
van Puijvelde GHM, Habets KLL, Theune CA, vvan Wanrooij EJA, de Vos P, Hauer AD, van Berkel TJC, Kuiper J: Effect of NKT cell activation on atherosclerosis depends on the presence of apoE. Submitted for publication
Van Es T, Hauer AD, van Puijvelde GHM, vvan Wanrooij EJA, de Vos P, Peterse N, van Berkel TJC, Kuiper J: DNA vaccination against IL-17 attenuates atherosclerosis in LDL receptor deficient mice. Submitted for publication.
Van Es T, Michon IN, vvan Wanrooij EJA, de Vos P, Peterse N, van Berkel TJC, Kuiper J: IL-15 aggravates atherosclerotic lesion development in LDL receptor deficient mice. Submitted for publication.
Stitzinger M, von der Thusen JH, vvan Wanrooij EJA, de Vos P, van Berkel TJC, Biessen EAL, van Snick J, Kuiper J: The role of IL-9 in Atherosclerosis and its Application in the Prevention of Atherogenesis. Submitted for publication.
Manuscripts in preparation
Van Wanrooij EJA, van Puijvelde GHM, Happe H, de Vos P, Habets K, van Berkel TJC, Kuiper J: Vaccination against CD127 severely aggravates atherosclerosis in LDLr deficient mice. Manuscript in preparation.
Van Wanrooij EJA, Volger OL, De Vos,P, Michon I, Horrevoets AJ, Van Berkel TJC, Kuiper J: Transcriptional profiling of initial atherogenesis in LDL receptor deficient mice identifies diet induced upregulation of FOXO1 controlled genes.
Manuscript in preparation.
Van Wanrooij EJA, Volger OL, De Vos,P, Twisk J, Horrevoets AJ, Van Berkel TJC, Kuiper J: Transcriptional profiling of CD4 T cells during diet induced atherogenesis. Manuscript in preparation.
Van Wanrooij EJA, Segers FME, Willemse ME, de Vos P, Peterse N, van Berkel TJC, Biessen EAL, Kuiper J: Vaccination against IL-16 accelerates atherogenesis in LDL receptor deficient mice. Manuscript in preparation.
van Puijvelde GHM, van Es T, Theune CA, Habets KLL, van Wanrooij EJA, van Es T, van Berkel TJC, Kuiper J: Endogenous ligands for NKT cells in atherosclerosis. Manuscript in preparation.
Van Es T, Michon IN, vvan Wanrooij EJA, de Vos P, van Berkel TJC, Kuiper J:
Leukocyte IL-17 receptor deficiency results in a reduction in atherosclerotic lesion development in LDL receptor knockout mice. Manuscript in preparation.
Peer reviewed abstracts accepted for presentation Scientific sessions American Heart Association
Interruption of the TNFRSF4/TNFSF4 Ligand Pathway Attenuates Atherogenesis in LDL Receptor Deficient Mice. E.J.A. Van Wanrooij, G. van Puijvelde, P. de Vos, H. Yagita, T. van Berkel, J. Kuiper. Circulation Supplement 2006;253:II-23
CD127 is Required for Macrophage and Regulatory T Cell Function and Has a Protective Role in Atherosclerosis. E.J.A. Van Wanrooij, G. van Puijvelde, H.
Happé, P. de Vos, T. van Berkel, J. Kuiper. Circulation Supplement 2006;1486:II- 286
OxLDL-Pulsed Dendritic Cells: An Immunotherapy in Atherosclerosis.
K.L.L.Habets, G.H.M. van Puijvelde, L.M. van Duivenvoorde, EE.J.A. van Wanrooij, P. de Vos, J.W. Cohen Tervaert, Th. J. C van Berkel, R.E.M. Toes, J.
Kuiper. Circulation Supplement 2006;1350:II-256
Immunomodulation with OCH-Primed Dendritic Cells Ameliorates Atherosclerosis. G.H.M. van Puijvelde, K.L.L. Habets, R.E.J. Litjens, L.M. van Duivenvoorde, EE.J.A. van Wanrooij, P. de Vos, G.A. van der Marel, H.S.
Overkleeft, J. Cohen Tervaert, T.J.C. van Berkel, R.E. Toes, J. Kuiper. Circulation Supplement 2006;1352:II-257
DNA vaccination Against IL-17 Attenuates Atherosclerosis in LDL Receptor Deficient Mice. T. van Es, A.D. Hauer, G.H.M. van Puijvelde, E.J.A. van Wanrooij, P. de Vos, N. Peterse, T.J.C. van Berkel, J. Kuiper. Circulation Supplement 2006;1353:II-257
Vaccination against CD99 inhibits atherogenesis in LDL receptor deficient mice.
EJA van Wanrooij, G. Bixel, D. Vesteweber, T.J.C van Berkel, J. Kuiper.
Circulation Supplement 2005;1336:II-263
The chemokine receptor antaginst TAK-779 attenuates atherogenesis EEva J.A.
van Wanrooij, Hester Happé, Paula de Vos, Takeshi Imanishi, Hiromi Fujiwara, Theo J.C. van Berkel, Johan Kuiper. Circulation Supplement 2004
Cathepsin S expression level is critical in atherosclerotic lesion homeostasis. J.H.
von der Thusen, R. de Nooier, EE.J.A.van Wanrooij, T.J.C. van Berkel, M.C. Lai, E.A.L. Biessen. Circulation Supplement 2002;106:II-215-216
International Vascular Biology Meeting.
Vaccination against CD99 inhibits atherogenesis in LDL receptor deficient mice.
EJA van Wanrooij, G. Bixel, D. Vesteweber, T.J.C van Berkel, J. Kuiper. 2006
Vascular lipid homeostasis during high cholesterol diet feeding in LDL recpetor deficient mice. EEJA van Wanrooij, T.J.C. van Berkel, J. Kuiper. Cardiovascular pathology2004;P042-S30
Appendix 1: List of PCR primers
GENE REVERSE PRIMER FORWARD PRIMER
36B4 GGACCCGAGAAGACCTCCTT GCACATCACTCAGAATTTCAATGG ABCB10 CAGAAACGTGCACTTCACATACC GATGGAAAGACTGAAATCCTGGA
CCL8 AGCTACGAGAGAATCAACAATATCCA CAGAGAGACATACCCTGCTTGGT CCR2 CCTTGGGAATGAGTAACTGTGTGA TGGAGAGATACCTTCGGAACTTCT CCR3 TGCAGGTGACTGAGGTGATTG CGGAACCTCTCACCAACAAAG CCR5 GACTGTCAGCAGGAAGTGAGCAT CTTGACGCCAGCTGAGCAA CD 4 GTGAGCTGGAGAACAGGAAAGAG GGCTGGTACCCGGACTGA
CD127 TACCGTGAGCGACAAAGATG GCTGAATCATTGGGTCACCT CD134 GCCTTCAAAGAACTACCTAGGGACTATG GCTCTCCTGGTTTTCTTTGCA
CD25 GGAGCCGCAAGCTAAAAGC TGCCTTCGTGCCCACTGT CD28 AGACTCCTTCAAGTGACTACCATGAAC GGGCTGGTAAGGCTTTCGA CD40 GGTAAGATGGCTTTTGTGGGTAAA GAAGTCCCAGGGATCAAAATCA CD68 CCTCCACCCTCGCCTAGTC TTGGGTATAGGATTCGGATTTGA CD69 AAAGCACGAGCGATCCAGTTA AGAAAAT AATTCGTTCCTCACCAACTA CD99 GCCGCTGCATCAGTGATG TTGTGAGTGGAGGTTATGATGTCA CTLA-4 GGACCACAAAGGGCTTGATC CGAGGTCCTGCACCAACTG CXCL10 GGATGGCTGTCCTAGCTCTGTAC CCTGGGCATGGCACATG
CXCR3 GCTGCTGTCCAGTGGGTTTT AGTTGATGTTGAACAAGGCGC FOXP3 GGAGCCGCAAGCTAAAAGC TGCCTTCGTGCCCACTGT
GITR GCCCTATGGCTGCCTTTCTC GCTAAACGTGGTGCTCTTGGT HMGcoAred. TCTGGCAGTCAGTGGGAACTATT CCTCGTCCTTCGATCCAATTT
HPRT TTGCTCGAGATGTCATGAAGGA AGCAGGTCAGCAAAGAACTTATAG IFN ATAACTATTTTAACTCAAGTGGCATAGATG T TCT GGC TCT GCA GGA TTT TCA
Il-10 TCTTACTGACTGGCATGAGGATCA GTCCGCAGCTCTAGGAGCAT Il-12 GACCAAAGGGACTATGAGAAGTATTCA CTGCTGCCGTGCTTCCA IL-16 AGGCAACGAGGTTCTTTCCA CCGAGCTTGGCGAAGGATA IL-17 CCAGGGAGAGCTTCATCTGTGT AAGTCCTTGGCCTCAGTGTTTG Il-1 TGG TGT GTG ACG TTC CCA TTA AGGTGGAGAGCTTTCAGCTCATAT
IL-2 TGCCAATTCGATGATGAGTCA GGCTTGTTGAGATGATGCTTTG IL-4 ACTTGAGAGAGATCATCGGCATTT AGCACCTTGGAAGCCCTACAG IL-6 GAAGAATTTCTAAAAGTCACTTTGAGATCTA CAC AGT GAG GAA TGT CCA CAA AC
Il-9 CCGTGCTACAGGGAGGGA TGGAAAACAGGCAAGAGTCTTG MCP-1 GCATCTGCCCTAAGGTCTTCA TTCACTGTCACACTGGTCACTCCTA MIP-1D CCAGGGTTCTCAGCACCAAT CTTCTCTGGGTTGGCACACA RANTES GCAAGTGCTCCAATCTTGCA CTTCTCTGGGTTGGCACACA
TGF AGGGCTACCATGCCAACTTCT GCAAGGACCTTGCTGTACTGTGT TNF GCCAGCCGATGGGTTGTA AGGTTGACTTTCTCCTGGTATGAG A
vWF AACTTCAATAAGAGCAAGGAGTTCGT ACTGAGATGCGCGTTGCAT
Appendix 2: Abbreviations
36B4 acidic ribosomal phosphoprotein PO
Ab antibody
ABC ATP binding casette APC antigen presenting cell
apoE/apoB apolipoprotein E/apolipoprotein B CCR/CXCR CC/CXC chemokine receptor CCL/CXCL chemokine ligand
CD cluster of differentiation CMV Cytomegalovirus
CTLA cytotoxic T-lymphocyte antigen CVD cardiovascular disease
DC dendritic cell
EAE experimental acquired encephalomyelitis FABP fatty acid binding protein
FACS fluorescent-activated cell sorting FMLP formyl-met-leu-phe
Foxp3 forkhead box p3
GFP green-fluorescent protein GSEA gene set enrichment analysis HDL high-density lipoprotein
HMG-coA 3-hydroxy-3-methylglutaryl coenzyme A HPRT hypoxanthine-guanine phophoribosyltransferase ICE interleukin-1 converting enzyme
i.p. intraperitoneal i.v. intravenous
ICAM-1 intercellular adhesion molecule-1 IFN interferon
Ig immunoglobulin IL interleukin
IP-10 interferon inducible protein
ITAC interferon inducible T cell -chemoattractant (ox)LDL (oxidized) low-density lipoprotein
LDLr low-density lipoprotein receptor LPS lipopolysaccharide
MCP-1 monocyte chemotactic protein MHC major histocompatibility complex MIG monokine induced by interferon MIP-1 macrophage inflammatory protein-1 MMP matrix metalloproteinase
NFAT nuclear factor of activated T cells NF-B nuclear factor B
NK natural killer
NKT cell natural killer T cell
oxLDL oxidized low-density lipoprotein PBS phophate buffered saline
PPAR peroxisome proliferators-activated receptor
RANTES regulated on activation, normal T cell expressed and secreted SMC smooth muscle cell
SR scavenger receptor TCR T cell receptor
TGF transforming growth factor Th1/Th2 T helper 1/T helper 2 TNF tumor necrosis factor Tr1 regulatory T cell type 1 Treg regulatory T cell
TUNEL terminal deoxynucleotidyl transferase end-labeling VCAM-1 vascular cell adhesion molecule-1
VLDL very low-density lipoprotein
